Bionova Scientific and Syenex forged a plasmid DNA manufacturing alliance intended to expand global access to plasmids for lentiviral and mRNA production, combining Bionova’s IS‑free host platform with Syenex’s delivery technologies. The deal targets reproducibility and regulatory robustness for upstream gene‑delivery inputs. Aragen Biologics unveiled CHOMax, a CHO cell line development and early manufacturing platform designed to compress timelines from DNA to IND‑enabling clinical supply. Both moves reflect escalating demand for scalable, phase‑appropriate CMC workflows as cell and gene developers prepare IND submissions.